Paul, Weiss, Rifkind, Wharton & Garrison LLP HAS announced that Ian Edvalson has joined the firm in San Francisco as a partner in the Corporate Department […]
Paul Weiss Adds Life Sciences Transactions Partner Ian Edvalson in San Francisco
Gilead Sciences Acquires Arcellx in $7.8 Billion Deal
Wilson Sonsini Goodrich & Rosati has advised Arcellx on the transaction, and Ropes & Gray LLP has advised Gilead Sciences. Gilead Sciences (Nasdaq: GILD) has entered...
Juvena Therapeutics Secures $33.5 Million in Series B Financing
Fenwick & West and Wilson Sonsini Goodrich & Rosati have advised Juvena Therapeutics. Juvena Therapeutics, a clinical-stage biotechnology company, has raised $33.5 million in a Series...
Natera Acquires Foresight Diagnostics in $450 Million All-Stock Transaction
Wilson Sonsini Goodrich & Rosati has advised Foresight Diagnostics, and Gibson Dunn has advised Natera, Inc. Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA...
ABL Bio Announces Equity Investment Agreement with Lilly
Wilson Sonsini Goodrich & Rosati has advised ABL Bio. ABL Bio has announced the signing of an equity investment agreement valued at KRW 22 billion with...
Iambic Raises Over $100 Million in Oversubscribed Financing Round
Wilson Sonsini Goodrich & Rosati has advised Iambic. Iambic, a clinical-stage life science and technology company, has announced the completion of an oversubscribed financing round, raising...
Foresight Diagnostics Grants Roche Sublicense for PhasED-Seq Technology in Non-Hodgkin’s Lymphoma
Wilson Sonsini Goodrich & Rosati has advised Foresight Diagnostics. Foresight Diagnostics has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems...
Kumquat and Bayer Enter $1.3 Billion Global License for KRAS G12D Inhibitor
Wilson Sonsini Goodrich & Rosati has advised Kumquat Biosciences Inc., and Baker McKenzie advised Bayer. Kumquat Biosciences Inc., a clinical-stage biotechnology company focused on oncology, has...
LENZ Therapeutics Secures FDA Approval for VIZZ in Presbyopia Treatment
Wilson Sonsini Goodrich & Rosati has advised LENZ Therapeutics on the transaction. LENZ Therapeutics announced that the U.S. Food and Drug Administration has approved VIZZ (aceclidine...
Juvena Therapeutics Enters $650 Million Research Collaboration with Eli Lilly
Wilson Sonsini Goodrich & Rosati has advised Juvena Therapeutics on the transaction. Juvena Therapeutics, Inc., a clinical-stage biotechnology company, has entered into a global licensing and...
ABL Bio’s Worldwide Licensing Agreement with GSK
Wilson Sonsini Goodrich & Rosati advised ABL Bio on the transaction. Simmons & Simmons has advised GSK. ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company...
Biolog’s Acquisition of Anaerobe Systems
Wilson Sonsini Goodrich & Rosati advised Anaerobe Systems on the transaction. Biolog, a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification...